3Spine has announced the appointment of Pierce Nunley, director of the Spine Institute of Louisiana (Shreveport, USA), to its medical advisory board.
The appointment was made at the International Society for the Advancement of Spine Surgery (ISASS) 2022 meeting (1–4 June; The Bahamas)
Nunley is also chairman of the American Board of Spine Surgery, and an associate professor at Louisiana State University. In addition, he has served as the designated principal investigator on over 30 clinical research studies.
Nunley joins existing medical advisory board members Domagoj Coric (Charlotte, USA), who is the current ISASS president and national principal investigator for 3Spine’s real-world evidence fusion study; Jeff Goldstein (New York, USA), ISASS past president and national principal investigator for the upcoming BalancedBack investigational device exemption (IDE) study; biomechanics researcher Avinash Patwardhan (Vienna, USA); Louis Nel (Pretoria, South Africa) and Robert Dunn (Cape Town, South Africa), who have each followed BalancedBack patients since 2007.
“I am honoured to be included in this pioneering group,” said Nunley. “3Spine’s total joint replacement has a real potential to change care for millions of people. We have a lot of work to do to get this to market, but I can tell you patients ask for lumbar motion in my practice every day. The potential is enormous.”
Scott Hodges, co-founder and medical director of 3Spine, added: “Pierce is a friend and a real technology leader. He is one of the few surgeons I know who can look into the future and see change, who also has the scientific, business, and teambuilding experience to make it happen. There is a reason you see Pierce on so many projects, and I am thrilled that he is part of ours.”
3Spine’s MOTUS device, the implant used in the BalancedBack total joint replacement procedure, replaces the function of the disc and facet joints through a posterior approach. The procedure broadly addresses leg pain, back pain, and spinal instability, while correcting posture and restoring freedom of movement and natural balance through reconstruction of the functional spinal unit.
MOTUS was first used in South Africa in 2007, and was designated a breakthrough device designation by the US Food and Drug Administration in 2020. Phase one clinical outcomes are published and its phase two US clinical study is currently pending IDE approval.